Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Sanovas receives patent for Multi-Balloon Catheter for Extravasated Drug Delivery

Sanovas Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office issued patent # 8,540,667 for the company's Multi-Balloon Catheter for Extravasated Drug Delivery.

29 Oct 2013

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

New unique nanostructure to target drug-delivery treatment of cancer cells

A unique nanostructure developed by a team of international researchers, including those at the University of Cincinnati, promises improved all-in-one detection, diagnoses and drug-delivery treatment of cancer cells.

29 Oct 2013

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Pulmatrix today announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200.

29 Oct 2013

Middle Peak Medical raises additional $3M in Series A financing

Middle Peak Medical, a development-stage medical device company that will commercialize a novel technology for treating mitral valve disease, has raised an additional $3M in a second closing of its over-subscribed Series A financing, which now totals approximately $11M.

28 Oct 2013

APR's Nexodyn receives European CE approval

APR announces the grant of the European CE approval of Nexodyn, a newly developed innovative product intended for use in a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers.

28 Oct 2013

MIT researchers design stealth drug delivery system to attack TNBC cells

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study in the journal ACS Nano focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

25 Oct 2013

Researchers use nanopores to smuggle DNA or proteins across membranes

A living cell is built with barriers to keep things out - and researchers are constantly trying to find ways to smuggle molecules in.‬ ‪Professor Giovanni Maglia (Biochemistry, Molecular and Structural Biology, KU Leuven) and his team have engineered a biological nanopore that acts as a selective revolving door through a cell's lipid membrane. The nanopore could potentially be used in gene therapy and targeted drug delivery.‬‬‬‬‬‬‬

24 Oct 2013

Nanometric scale diamond particles offer new way to detect cancer far earlier

Real-time monitoring of cancer cell processes could soon be possible thanks to nanometric scale diamonds used as biosensors.

24 Oct 2013

Biocompatible compounds can be used to develop customized implant designs with 3-D printing

Researchers from North Carolina State University, the University of North Carolina at Chapel Hill and Laser Zentrum Hannover have discovered that a naturally-occurring compound can be incorporated into three-dimensional (3-D) printing processes to create medical implants out of non-toxic polymers.

24 Oct 2013

InnoCore, Allergan expand collaboration to develop ophthalmology medicines

InnoCore Pharmaceuticals today announced that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc., a multi-specialty health care company headquartered in Irvine, California.

22 Oct 2013

Levemir FlexTouch insulin pen receives approval from Health Canada for treatment of diabetes

Novo Nordisk today announced that Health Canada has approved Levemir® FlexTouch®, a disposable prefilled insulin pen containing Levemir® (insulin detemir). Levemir® FlexTouch® has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes).

19 Oct 2013

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

pSivida Corp., a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc. has received a Complete Response Letter for the New Drug Application for ILUVIEN from the U.S. Food and Drug Administration.

18 Oct 2013

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.

18 Oct 2013

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate its AEROSURF phase 2 clinical program.

17 Oct 2013

New injection device to reduce fear and pain of injecting modern medicines

...

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

New combinations of postoperative pain treatment decreased both pain and use of pain relievers

New combinations of postoperative pain treatment decreased both pain and the use of narcotic pain relievers according to two studies presented this week at the 2013 Clinical Congress of the American College of Surgeons.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

7 Oct 2013

Drug Delivery News and Research

Further Reading

Sanovas receives patent for Multi-Balloon Catheter for Extravasated Drug Delivery

Cytrx announces Q3 2013 financial results, provides clinical update

New unique nanostructure to target drug-delivery treatment of cancer cells

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Middle Peak Medical raises additional $3M in Series A financing

APR's Nexodyn receives European CE approval

MIT researchers design stealth drug delivery system to attack TNBC cells

Researchers use nanopores to smuggle DNA or proteins across membranes

Nanometric scale diamond particles offer new way to detect cancer far earlier

Biocompatible compounds can be used to develop customized implant designs with 3-D printing

InnoCore, Allergan expand collaboration to develop ophthalmology medicines

Levemir FlexTouch insulin pen receives approval from Health Canada for treatment of diabetes

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

New injection device to reduce fear and pain of injecting modern medicines

FDA approves OTREXUP injection for adults with RA, children with active pJIA

New combinations of postoperative pain treatment decreased both pain and use of pain relievers

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Event guide: World ADC Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo